rdf:type |
|
lifeskim:mentions |
|
pubmed:issue |
4
|
pubmed:dateCreated |
2006-7-11
|
pubmed:abstractText |
To analyze our experience with the new, 5 mg intranasal formulation of zolmitriptan in the symptomatic treatment of migraine attacks.
|
pubmed:language |
spa
|
pubmed:journal |
|
pubmed:citationSubset |
IM
|
pubmed:chemical |
|
pubmed:status |
MEDLINE
|
pubmed:month |
May
|
pubmed:issn |
0213-4853
|
pubmed:author |
|
pubmed:issnType |
Print
|
pubmed:volume |
21
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
188-91
|
pubmed:dateRevised |
2010-11-18
|
pubmed:meshHeading |
pubmed-meshheading:16832773-Administration, Intranasal,
pubmed-meshheading:16832773-Adolescent,
pubmed-meshheading:16832773-Adult,
pubmed-meshheading:16832773-Aged,
pubmed-meshheading:16832773-Female,
pubmed-meshheading:16832773-Humans,
pubmed-meshheading:16832773-Male,
pubmed-meshheading:16832773-Middle Aged,
pubmed-meshheading:16832773-Migraine Disorders,
pubmed-meshheading:16832773-Oxazolidinones,
pubmed-meshheading:16832773-Serotonin Receptor Agonists,
pubmed-meshheading:16832773-Tryptamines
|
pubmed:year |
2006
|
pubmed:articleTitle |
[Symptomatic treatment of migraine with zolmitriptan: experience with 82 patients].
|
pubmed:affiliation |
Servicio de Neurología, Hospital Universitario de Salamanca. juliopascual@telefonica.net
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
English Abstract
|